Fig. 5 | Scientific Reports

Fig. 5

From: Association between glucagon-like peptide-1 receptor agonist therapy and respiratory illness in patients with type 2 diabetes: a retrospective observational cohort study

Fig. 5

Risk of other lung conditions in patients using GLP-1 RAs versus other antidiabetic medications. Risk of other lung conditions includes A influenza and pneumonia, B acute lower lung infection, C suppurative lung disease, and D pulmonary fibrosis. The vertical line indicates an HR of 1.00. A lower 95% CI limit of > 1.00 indicates a markedly higher risk. GLP1-RA glucagon-like peptide-1 receptor agonist, SGLT2i sodium–glucose cotransporter 2 inhibitor, HR hazard ratio, CI confidence interval.

Back to article page